Boston, United States
Tango Therapeutics is a clinical-stage biotechnology company, established in 2017, focused on developing precision medicines to target cancer by exploiting tumor suppressor loss. Its mission is encapsulated in the slogan: "Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines."
Headquartered in the United States, the company advances its research through a sophisticated understanding of genetic subtypes of cancer. By utilizing CRISPR-based target discovery and synthetic lethality, Tango Therapeutics aims to develop treatments offering deeper, sustained benefits, minimizing off-target effects by sparing normal cells.
Tango's growth trajectory includes a significant $186 million post-IPO equity investment on August 11, 2021, backed by major investors like Casdin Capital, RA Capital Management, and Gilead Sciences. Initially launched with a $55 million Series A from Third Rock Ventures, Tango is positioned to swiftly transition novel discoveries into transformative therapies within defined cancer patient populations.
Pear Bio
Inspirna, Inc.
